Q&A with John Plachetka, POZEN - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Q&A with John Plachetka, POZEN
A Q&A with John Plachetka, chair, president, and CEO of POZEN, on recent industry trends.

Pharmaceutical Technology
Volume 35, Issue 9, pp. 84


John Plachetka
PharmTech:
What is the biggest industry challenge you're now facing?

Plachetka:
The biggest challenge that POZEN sees in the healthcare industry is bringing novel therapies to market in a way that is efficient and affordable to customers, yet also meets FDA's development guidelines. The traditional Big Pharma model has become obsolete. It has stifled innovation and led to a decline in the approval of novel drugs and the continued rise of healthcare costs. POZEN's business model is designed to avoid some of the pitfalls of traditional drug development and commercialization. The company works under compressed timetables, compared with larger pharmaceutical companies, and uses an in-source model that employs a small expert team that leads the drug-development and commercial strategies, while working closely with strategic partners.

PharmTech:
Do you see a new industry trend emerging?

Plachetka:
One current trend that we see in the industry is in the development of novel combination therapies. POZEN has been researching how to best integrate existing medicines to achieve superior outcomes since I founded the company in 1996. We believe that the benefits of many gold-standard medicines today are not fully realized because of tolerability, safety, or efficacy concerns for certain patient types. Recently, FDA and the industry have begun to recognize the potential of integrated therapies, and FDA is evaluating how to update development guidance. POZEN is currently developing a family of products to maximize the benefits of aspirin by reducing its associated gastrointestinal damage.

PharmTech:
How do you stay abreast of new developments in the industry?

Plachetka:
We hold close, strategic relationships both in and outside of the pharmaceutical industry and frequently participate in conferences and seminars. We regularly read medical journals and industry trade publications. To remain in touch with the demands of our customers, we actively conduct market research.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
Source: Pharmaceutical Technology,
Click here